Biotech | December 14, 2021
Moderna to set up mRNA vaccine manufacturing facility in Australia
Up to 100 million mRNA vaccine doses could be produced in Australia each year
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
The company will manufacture a cancer immunotherapy product from 2022
The proposed week-long event will comprise specific themes - International engagements, market access and incubation support, funding support to startups etc. and will cover the different areas of the innovation lifecycle
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare
The company will donate 5000 nebulizers to primary health care centres in rural India
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The platform’s technology works as a compression algorithm for molecular testing
Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
Subscribe To Our Newsletter & Stay Updated
